Precise, Personalized Monitoring
Sequenta is dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. Initially formed around a profound revolution in the cost of DNA sequencing the company is developing brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes. The incredible diversity created by these genes are at the heart of a large number of conditions critical to human health and disease allowing the company to be in a position to inform a large number of clinical decisions.
Facts & Stats
- The company was founded in 2008 by entrepreneurs who previously founded ParAllele BioScience, a successful startup company sold to Affymetrix in 2005.
- Sequenta has developed assays that enable the revolution in next generation sequencing to be brought to bear on the task of immune system profiling.
- Acquired by Adaptive Biotechnology in 2015.